Wolverine (BPC-157 + TB-500) — Dual-Mechanism Comprehensive Tissue Repair Research Peptide Combination | Klene Peptides

For Research Use Only | Not for Human or Veterinary Administration

Wolverine is Klene Peptides’ branded research combination of two of the most extensively studied tissue-repair peptides: BPC-157 (Body Protection Compound-157) and TB-500 (synthetic thymosin beta-4). While each peptide independently demonstrates significant tissue-protective, pro-angiogenic, and anti-inflammatory activity, their simultaneous administration engages complementary and mechanistically distinct biological repair pathways. BPC-157 operates primarily through VEGFR2/NO-driven angiogenesis, growth hormone receptor sensitization, and mucosal and musculoskeletal cytoprotection; TB-500 operates through actin dynamics regulation, cardiac and neural cytoprotection, and ILK/Akt survival signaling. The research hypothesis driving Wolverine combination studies is that this mechanistic complementarity produces broader, more comprehensive tissue repair engagement than either compound alone. Klene Peptides supplies Wolverine to USA research institutions with verified purity for both components and same-day fulfillment.

Every vial from Klene Peptides includes:

Chemical Identity & Structural Profile

BPC-157 (Component 1)

Parameter	Value
Full Name	Body Protection Compound-157
Sequence	Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Amino Acid Count	15 (pentadecapeptide)
Molecular Weight	1,419.55 g/mol
CAS Number	137525-51-0
Primary Targets	VEGFR2, GH receptor, eNOS/NO pathway, FAK/paxillin
Storage	Lyophilized: −20°C; Reconstituted: 4°C, use within 14 days

TB-500 (Component 2)

Parameter	Value
Full Name	Thymosin Beta-4 (synthetic) / TB-500
Sequence Length	43 amino acids
Key Functional Motif	LKKTET (actin-binding domain, residues 17–22)
Molecular Weight	~4,963 Da
CAS Number	77591-33-4
Primary Targets	G-actin, VEGF, ANG-1, ILK/Akt, FoxO3a, eNOS
Storage	Lyophilized: −20°C; Reconstituted: 4°C, use within 28 days

Mechanism of Action — Complementary Pathway Architecture

Side-by-Side Mechanism Comparison

Mechanism	BPC-157	TB-500	Combined Research Rationale
Angiogenesis	VEGFR2 upregulation → vessel formation	ANG-1 + VEGF → vessel maturation and stabilization	Coordinated new vessel formation and pericyte-stabilized maturation
eNOS/NO pathway	Direct eNOS upregulation → perfusion	ANG-1-mediated eNOS activation	Additive NO-dependent tissue perfusion enhancement
Anti-inflammatory	NF-κB suppression, COX-2 downregulation	TNF-α/IL-1β reduction, M1→M2 macrophage polarization	Dual-mechanism broad-spectrum inflammation control
Cell migration	FAK/paxillin cytoskeletal activation	G-actin sequestration via LKKTET → dynamic cytoskeleton	Coordinated endothelial and fibroblast migration signals
Survival signaling	GH receptor sensitization; MAPK/ERK	ILK → Akt → NF-κB anti-apoptotic cascade	Dual survival pathway engagement across tissue types
Cardiac protection	Systemic cytoprotective signaling; NO production	ILK/FoxO3a cardiomyocyte survival; epicardial progenitor activation	Complementary cardiac repair signals
CNS protection	Dopaminergic stabilization; neuroprotective NO	Oligodendrogenesis; axonal sprouting; neuroinflammation reduction	Dual neuroprotective mechanism coverage

No pharmacokinetic interaction between the two peptides has been reported. They have independent metabolic pathways and can be co-administered in the same injection volume without physical incompatibility at research concentrations.

Pharmacokinetic Profiles (Combined Context)

Parameter	BPC-157	TB-500
Molecular Weight	1,419.55 g/mol	~4,963 Da
Primary Research Route	SC, IP, oral	SC, IP
Plasma Half-Life	~4–6 hours	~30 min – 2 hours
Key Active Metabolite	None identified	Ac-SDKP (anti-fibrotic, angiogenic)
Oral Activity	Demonstrated (gastric acid stable)	Not established for oral
Key Distribution	GI tract, tendon, liver, CNS	Cardiac, skeletal muscle, CNS

Research Applications

Musculoskeletal & Orthopedic Research

Tissue	BPC-157 Contribution	TB-500 Contribution	Combined Research Focus
Tendon	VEGFR2 angiogenesis; collagen synthesis	Cell migration; actin dynamics	Accelerated tendinopathy and tear healing
Skeletal muscle	NO-mediated perfusion; VEGF	Satellite cell activation; anti-fibrotic remodeling	Muscle crush and overuse injury models
Bone	GH-driven osteoblast proliferation signals	Angiogenic vascularization	Fracture and stress injury healing
Ligament	Collagen remodeling	VEGF/ANG-1 vascular ingrowth	Ligament-to-bone attachment repair

Cardiovascular & Cardiac Repair Research

Model	Mechanism	Research Focus
Post-MI recovery	TB-500 ILK/FoxO3a; BPC-157 NO production	Cardiomyocyte survival; infarct size reduction
Cardiac vascularization	TB-500 ANG-1; BPC-157 VEGFR2	Coronary arteriole density and maturation
Cardiomyopathy models	Combined anti-inflammatory + cytoprotective	Functional cardiac parameter preservation

Gastrointestinal Research

BPC-157 provides the primary GI-protective mechanism in this combination:

Wound Healing & Skin Repair

Wound Type	Combined Mechanism	Research Outcome
Full-thickness wounds	VEGFR2 + ANG-1 angiogenesis; TB-500 keratinocyte migration	Accelerated closure; improved tensile strength
Burns	Dual anti-inflammatory + neovascularization	Reduced necrosis zone; improved re-epithelialization
Diabetic wound models	Dual VEGF stimulation; NO-driven perfusion restoration	Improved healing in metabolically compromised models

Neurological Research

Research Dosing Reference

For scientific reference only — not prescriptive recommendations

Component	Reported Dose Range	Route	Duration
BPC-157	10–100 mcg/kg/day	SC, IP, oral	7–28 days
TB-500	150–300 mcg per animal (rodent)	SC, IP	2–4 weeks
Combined	Each at standard individual research dose	SC (co-administered or separate)	Per protocol design

Dosing derived from independent published preclinical literature for each component.

Reconstitution Reference

Component	Lyophilized Amount	Bacteriostatic Water	Concentration
BPC-157	5 mg	2.5 mL	2.0 mg/mL
TB-500	5 mg	2.5 mL	2.0 mg/mL

Both components may be reconstituted separately and co-administered in the same injection volume. No incompatibility between components has been reported in the research literature.

Klene Peptides Quality Standards

Certificate of Analysis — Standard Parameters

Every Wolverine batch from Klene Peptides is verified for each component against the following analytical benchmarks:

Test	Specification	Method
Purity — BPC-157	≥99%	HPLC (High-Performance Liquid Chromatography)
Purity — TB-500	≥99%	HPLC (High-Performance Liquid Chromatography)
Molecular Identification (both)	Confirmed	HPLC-MS (High-Performance Liquid Chromatography – Mass Spectrometry)
Water Content	<1.5%	—

What Every Klene Peptides Order Includes

Ordering Wolverine (BPC-157 + TB-500) for Your Research Program

Important Research Compliance Notice

All products sold by Klene Peptides are strictly for in vitro research and laboratory investigation purposes only. Wolverine (BPC-157 + TB-500) supplied by KlenePeptides.net has not been evaluated by the FDA for human safety or efficacy. It is not approved for human or veterinary administration. Purchase, possession, and use must comply with all applicable federal, state, and local regulations. This content is intended for licensed researchers and qualified scientific personnel only.

Scientific References

BPC-157:

Sikiric P, et al. "Body Protection Compound-157: Pharmacology and Biochemistry." Curr Pharm Des. 2018;24(18):1990-2001.
Chang CH, et al. "The promoting effect of pentadecapeptide BPC 157 on tendon healing." J Appl Physiol. 2011;110(3):774-80.
Gwyer D, et al. "Gastric pentadecapeptide BPC 157 and its role in the healing process." Int J Mol Sci. 2019;20(8):1781.

TB-500: 4. Bock-Marquette I, et al. "Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair." Nature. 2004;432(7016):466-472. 5. Smart N, et al. "Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization." Nature. 2007;445(7124):177-182. 6. Goldstein AL, et al. "Thymosin beta-4 is a multifunctional regenerative peptide." Ann N Y Acad Sci. 2012;1270:93-99.
Combination Rationale: 7. Sikiric P, et al. "Stable gastric pentadecapeptide BPC 157 and its role in cytoprotection and adaptive cytoprotection." Curr Pharm Des. 2010.